TGA provisionally approves Pfizer's COVID-19 vaccine, COMIRNATY (tozinameran), for use as a booster dose in individuals 5 years and older

On 20 September 2022, the Therapeutic Goods Administration (TGA) provisionally approved Pfizer's COVID-19 vaccine, COMIRNATY (tozinameran) for use as a booster dose in individuals 5 years to 11 years.

As with all COVID-19 vaccines, the Government's decision on the use of this vaccine as a booster in this age group will be informed by advice from the Australian Technical Advisory Group on Immunisation (ATAGI)

Further information relating to the TGA’s decision can be found in the Product Information (PI) document, available on the TGA website. The Australian Public Assessment Report for this decision will be published in the coming days.

Contact for members of the media:

• Email: news@health.gov.au
• Phone: 02 6289 7400